IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-57774-x.html
   My bibliography  Save this article

Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase II trial

Author

Listed:
  • Hui-Sheng Chen

    (General Hospital of Northern Theater Command)

  • Zi-Ai Zhao

    (General Hospital of Northern Theater Command)

  • Xin-Yu Shen

    (General Hospital of Northern Theater Command)

  • Si-Qi Qiu

    (General Hospital of Northern Theater Command)

  • Yu Cui

    (General Hospital of Northern Theater Command)

  • Jing Qiu

    (General Hospital of Northern Theater Command)

  • Wei Li

    (General Hospital of Northern Theater Command)

  • Hong Zhang

    (General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group)

  • Wen-Huo Chen

    (Zhangzhou Municipal Hospital)

  • Li-Hua Wang

    (The Second Affiliated Hospital of Harbin Medical University)

  • De-Hui Zhang

    (Panjin Central Hospital)

  • Ying Chen

    (Huludao Central Hospital)

  • Yu-Tong Ma

    (Beipiao Central Hospital)

  • Zong-En Gao

    (Shengli Oilfield Central Hospital)

  • Shou-Chun Wang

    (The First Hospital of Jilin University)

  • Di Li

    (Dalian Municipal Hospital)

  • Hua Liu

    (The Third People’s Hospital of Chengdu)

  • Thanh N. Nguyen

    (Neurology, Radiology, Boston Medical Centre)

Abstract

This phase II, randomized, double blinded, multi-center study aims to explore whether intravenous edaravone dexborneol (ED) could improve clinical outcomes in patients with anterior circulation stroke with successful endovascular reperfusion (ClinicalTrials.gov: NCT04667637). Eligible patients were randomly (1:1) assigned into ED, which received intravenous ED (37.5 mg, 2/day, for 12 days) or control group, which received placebo. The primary endpoint was favorable functional outcome (a modified Rankin Scale [mRS] of 0–2 at 90 days). Two hundred patients were enrolled, including 97 in ED group and 103 in control group. The proportion of patients with 90-day mRS (0–2) was 58.7% (54/92) in ED group and 52.1% (49/94) in control group (unadjusted odds ratio 1.37, [95% CI 0.76-2.44], P = 0.29). This work suggests that intravenous ED is safe, but do not statistically improve 90-day functional outcomes in patients with anterior circulation stroke with successful endovascular reperfusion.

Suggested Citation

  • Hui-Sheng Chen & Zi-Ai Zhao & Xin-Yu Shen & Si-Qi Qiu & Yu Cui & Jing Qiu & Wei Li & Hong Zhang & Wen-Huo Chen & Li-Hua Wang & De-Hui Zhang & Ying Chen & Yu-Tong Ma & Zong-En Gao & Shou-Chun Wang & Di, 2025. "Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase II trial," Nature Communications, Nature, vol. 16(1), pages 1-8, December.
    • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57774-x
    DOI: 10.1038/s41467-025-57774-x
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-57774-x
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-025-57774-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57774-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.